AbbVie is launching Humira on the TrumpRx platform with an 86% discount under a pricing agreement with the White House. The ...
Pfizer PFE and AbbVie ABBV are leading U.S. drugmakers with strong positions across multiple therapeutic areas. Oncology ...
It has been a tough market. The uncertainty surrounding the war with Iran is taking a toll. But one stock in particular should be worth enduring possible short-term downside for potentially sizable ...
Eli Lilly LLY and AbbVie ABBV are leading, well-established U.S. drugmakers with multiple blockbuster therapies, strong R&D ...
March 28 () - Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two ...
Zacks Investment Research on MSN
How will Skyrizi and Rinvoq shape AbbVie's Q1 immunology sales?
AbbVie ABBV is set to report first-quarter 2026 results on April 29, with investor focus likely to remain on its immunology ...
AbbVie’s Skyrizi appears to have stronger efficacy than Johnson & Johnson’s newly approved pill Icotyde, as well as a less frequent dosing schedule that patients could prefer, according to analysts at ...
Overcoming common challenges with today’s biologics, such as developing devices for high-concentration subcutaneous ...
Prescriptions for an adalimumab biosimilar among new users rose from 0% to 24% after CVS Caremark added it to its formulary, ...
The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the ...
The federal direct-to-consumer website TrumpRx.gov currently lists 54 brand-name medications accessible through manufacturer-run cash discount programs. That number is expected to grow, as the White ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results